What Is Aflibercept?

Aflibercept is a laboratory-made protein that acts as a soluble “decoy receptor.” It binds to vascular endothelial growth factor A, commonly called VEGF-A, as well as placental growth factor. By trapping these signaling proteins, aflibercept prevents them from activating receptors that encourage fragile blood vessels to grow or leak.

Excess VEGF activity plays an important role in several retinal disorders. Abnormal vessels may release blood or fluid beneath or within the retina, while damaged existing vessels can allow fluid to collect in the macula. The macula is the small central area responsible for detailed vision used for reading, recognizing faces, driving, and finding the television remote that was directly in front of you.

Reducing VEGF activity can dry the retina, limit further leakage, and stabilize or improve vision. The medicine does not permanently cure the underlying disease, however. Many patients need repeated injections and regular retinal imaging to keep the condition controlled.

What Is Eylea Used For?

Wet Age-Related Macular Degeneration

Neovascular, or wet, age-related macular degeneration occurs when abnormal blood vessels develop beneath the retina. These vessels can leak blood and fluid, causing blurred central vision, distortion, or a dark area in the visual field. Eylea can suppress this leakage and help prevent additional vision loss. Some patients also experience measurable improvement in visual acuity.

Macular Edema Following Retinal Vein Occlusion

A retinal vein occlusion develops when a vein carrying blood away from the retina becomes blocked. The blockage may involve a branch retinal vein or the central retinal vein. Pressure builds behind the obstruction, encouraging blood and fluid to leak into the retina. When swelling reaches the macula, vision can become blurry or distorted.

Aflibercept reduces the VEGF-driven leakage associated with retinal vein occlusion and may improve retinal thickness and vision. Treatment is often frequent at first because uncontrolled swelling can return.

Diabetic Macular Edema

Diabetic macular edema, or DME, is a complication of diabetic retinopathy. Chronically elevated blood sugar can damage small retinal blood vessels, making them weak and leaky. Fluid then collects in or near the macula.

Eylea injections can reduce retinal swelling and help preserve or improve central vision. Treatment works best as part of a broader diabetes plan that includes blood-sugar management, blood-pressure control, cholesterol management, smoking cessation, and regular dilated eye examinations.

Diabetic Retinopathy

Eylea is also approved to treat diabetic retinopathy, including disease that has not yet caused obvious visual symptoms. Anti-VEGF treatment can reduce the severity of abnormal retinal changes and lower the risk of progression in appropriately selected patients.

Improvement after an injection does not mean diabetes has stopped affecting the eyes. Continued systemic care and retinal monitoring remain essential.

Retinopathy of Prematurity

Eylea may be used in premature infants with retinopathy of prematurity, or ROP. In this condition, abnormal retinal blood vessels develop before the retina has finished maturing. Severe disease can lead to retinal detachment and permanent vision loss.

The infant dose is much smaller than the adult dose. Treatment and follow-up must be directed by an ophthalmologist experienced in neonatal retinal disease because abnormal vascular growth can recur after the initial response.

Eylea Dosage and Administration

The following schedules describe FDA-labeled dosing for standard Eylea 2 mg unless otherwise noted. A retina specialist may adjust visit timing according to retinal imaging, visual acuity, disease activity, previous response, and the condition being treated. Patients should never attempt to calculate, prepare, or administer aflibercept themselves.

Wet AMD Dosing

The recommended adult dose is 2 mg in 0.05 mL injected into the affected eye every four weeks for the first three months. Treatment is then generally continued every eight weeks.

Some patients need injections every four weeks after the loading phase. After one year of effective therapy, selected patients may be treated every 12 weeks, although this extended schedule was not as effective overall as dosing every eight weeks. Regular assessment is necessary because a comfortable calendar is not always the same thing as a dry retina.

Retinal Vein Occlusion Dosing

For macular edema following a branch or central retinal vein occlusion, the recommended dose is 2 mg in 0.05 mL every four weeks. The specialist determines how long monthly treatment should continue based on vision and retinal findings.

DME and Diabetic Retinopathy Dosing

For diabetic macular edema and diabetic retinopathy, the usual schedule is 2 mg every four weeks for the first five injections, followed by one injection every eight weeks.

Most patients do not gain additional benefit from continuing monthly treatment after the initial five doses, but some eyes do require more frequent injections. Treatment plans therefore depend on optical coherence tomography scans, retinal examination, vision testing, and the patient’s response over time.

Retinopathy of Prematurity Dosing

The recommended ROP dose is 0.4 mg in 0.01 mL injected into the affected eye. Both eyes may be treated on the same day using separate sterile supplies. Repeat treatment may be given when medically necessary, but injections into the same eye must be separated by at least 10 days.

Eylea Versus Eylea HD

Eylea HD contains a higher concentration that delivers 8 mg of aflibercept in 0.07 mL. It has its own indications and dosing intervals and is not simply four standard Eylea injections combined into one superhero-sized dose. The two formulations must not be substituted according to volume alone.

Patients should confirm whether their treatment is Eylea 2 mg, Eylea HD 8 mg, or an aflibercept biosimilar. The prescribing retina specialist should provide the schedule for the exact product being administered.

What Does Eylea Look Like?

Standard Eylea is supplied as a sterile, clear, colorless to pale-yellow solution. It is available in a single-dose prefilled glass syringe or a single-dose glass vial. The adult presentation is designed to deliver 2 mg of aflibercept in 0.05 mL.

Patients generally do not receive a retail box to take home because the medication is stored, prepared, and administered in a medical office or clinic. Official product photographs may show branded outer packaging, a labeled vial, or a prefilled syringe. Packaging can change, and biosimilar products may look different, so an online picture should never be used to verify medication identity.

Before administration, the clinical team checks the label, concentration, expiration date, and solution. A product containing particles, discoloration, or signs of damage should not be used.

Common Side Effects of Aflibercept

Many side effects are related to the injection procedure or temporary irritation of the eye. Common reactions reported with standard Eylea include:

• A small patch of blood on the white part of the eye
• Eye discomfort or pain
• Temporary blurry vision
• New or temporarily noticeable floaters
• A gritty or foreign-body sensation
• Watery eyes
• Redness
• Increased pressure inside the eye
• Vitreous detachment
• Cataract development or progression

A bright-red spot on the white of the eye can look alarming but is often a harmless conjunctival hemorrhage caused by a tiny surface blood vessel. It commonly fades over several days or weeks. Appearance alone cannot distinguish every harmless reaction from a serious complication, however, so patients should follow the clinic’s aftercare instructions.

Serious Side Effects Requiring Urgent Care

Endophthalmitis

Endophthalmitis is a rare but potentially vision-threatening infection inside the eye. Warning signs include increasing eye pain, worsening redness, sensitivity to light, rapidly decreasing vision, discharge, or a marked increase in floaters. These symptoms require immediate evaluation by an ophthalmologist. Waiting until the next scheduled appointment is not a suitable strategy.

Retinal Tear or Retinal Detachment

Intravitreal injections have been associated with retinal tears and detachments. Symptoms may include flashes of light, a sudden shower of floaters, loss of side vision, or a curtain-like shadow across the visual field. Emergency eye care is needed.

Retinal Vasculitis

Inflammation of retinal blood vessels, with or without vascular blockage, has been reported rarely after aflibercept injections. New pain, redness, light sensitivity, or worsening vision should be reported promptly.

Increased Intraocular Pressure

Pressure inside the eye may rise shortly after the injection. Repeated anti-VEGF treatment has also been associated with sustained pressure increases in some patients. The care team may measure eye pressure and assess blood flow to the optic nerve, particularly in people with glaucoma or other pressure-related concerns.

Arterial Thromboembolic Events

Because VEGF inhibitors enter the bloodstream in small amounts, there is a potential risk of arterial blood clots, including heart attack and stroke. The absolute risk following an eye injection is considered low, but patients should disclose any history of stroke, transient ischemic attack, heart attack, or blood-clotting problems.

Chest pain, sudden shortness of breath, facial drooping, one-sided weakness, severe sudden headache, confusion, or difficulty speaking requires emergency medical attention.

Severe Allergic Reaction

Seek urgent care for facial or throat swelling, hives, severe rash, trouble breathing, trouble swallowing, or other signs of anaphylaxis.

Who Should Not Receive Eylea?

Eylea is contraindicated in patients with:

• An infection in or around the eye
• Active inflammation inside the eye
• A known serious allergy to aflibercept or another ingredient in the product

An injection may need to be postponed when an eye is unusually red, painful, swollen, or producing discharge. Patients should also tell the specialist about recent eye surgery, glaucoma, retinal detachment, previous injection reactions, or recent cardiovascular events.

Pregnancy, Birth Control, and Breastfeeding

Adequate controlled studies of Eylea in pregnant people are not available. Animal studies found harmful effects on embryo-fetal development, and blocking VEGF could theoretically interfere with fetal blood-vessel development. Standard Eylea should be used during pregnancy only when the expected benefit justifies the potential fetal risk.

Patients who can become pregnant should use effective contraception before treatment, during treatment, and for at least three months after the final standard Eylea injection. Eylea HD has different contraceptive guidance, so patients receiving the 8 mg formulation should follow its specific prescribing information.

It is not known whether intravitreal aflibercept is present in human milk or what effect it might have on a breastfed infant. The benefits of breastfeeding, the parent’s need for treatment, and possible infant risks should be discussed with the ophthalmologist and obstetric or pediatric care team.

Aflibercept Drug and Food Interactions

Standard Eylea labeling does not identify a list of established drug-drug or food interactions. Because the medicine is placed directly into the eye and systemic exposure is limited, interactions are not expected to resemble those associated with ordinary oral medications.

That does not make the medication history optional. Patients should tell the retina specialist about all prescription drugs, over-the-counter medicines, vitamins, supplements, herbal products, and other eye treatments. The clinician should also know whether the patient receives another intravitreal medicine or has recently undergone eye surgery.

Patients taking aspirin, warfarin, apixaban, clopidogrel, or another medication affecting clotting may notice a surface blood spot after an injection. They should not stop a blood thinner without instructions from the clinician who prescribed it. For many patients, the danger of abruptly stopping anticoagulation is greater than the nuisance of a temporary red patch on the eye.

No special diet is normally required with aflibercept. Food and alcohol do not directly alter an injection already sitting inside the eye, although good diabetes and cardiovascular management can influence the retinal diseases being treated.

What Happens If an Eylea Appointment Is Missed?

Eylea is administered on scheduled treatment dates rather than taken daily. A patient who misses an appointment should call the retina clinic promptly to reschedule. Waiting for symptoms to worsen is risky because retinal fluid can return before the patient notices a change in vision.

Do not try to compensate by arranging two injections close together without specialist direction. The ophthalmologist will decide the safest revised schedule after evaluating the eye.

The Eylea Injection Experience: What Patients Can Expect

Before the Procedure

A typical appointment includes a vision test, pupil dilation, retinal examination, and often optical coherence tomography. OCT is a painless scan that creates detailed cross-sectional images of the retina. It helps the specialist see fluid that may be invisible to the patient and far too subtle for ordinary photography.

The clinician reviews changes in vision, recent illnesses, medication updates, previous injection reactions, and possible symptoms of infection. Patients should mention new redness, discharge, significant pain, recent stroke or heart attack, pregnancy, or planned eye surgery before the injection begins.

Transportation may be useful because dilating drops and the injection can blur vision temporarily. Sunglasses also help after dilation, unless walking outside while squinting like a confused movie detective is part of the afternoon plan.

During the Injection

The patient reclines in an examination chair. The eye and surrounding skin are cleaned with an antiseptic, usually a povidone-iodine solution, to reduce infection risk. Numbing drops, gel, or a small anesthetic injection may be used. An eyelid holder may keep blinking from interrupting the sterile field.

The ophthalmologist asks the patient to look in a particular direction and injects aflibercept through the white part of the eye. The injection itself generally lasts only a few seconds. Some people feel pressure, a brief pinch, or nothing at all. The needle is not aimed through the pupil, and patients usually do not watch it approaching.

A dark spot or floating bubble may appear immediately afterward as the medicine enters the vitreous gel. The clinic may check vision, eye pressure, or blood flow following the procedure.

The First Day After Treatment

Mild scratchiness, tearing, a small surface blood spot, or temporary blur can occur. These effects often improve within a day or two. Artificial tears may be recommended for irritation, but patients should use only products approved by their eye-care team. Rubbing the eye is best avoided.

Instructions about showering, swimming, contact lenses, makeup, exercise, and other activities vary by clinic and patient. The individualized aftercare sheet should take priority over generic internet advice.

Increasing pain, worsening redness, strong light sensitivity, rapidly declining vision, flashes, a curtain-like shadow, or a sudden surge in floaters is not a routine “wait and see” reaction. The retina specialist or emergency eye service should be contacted immediately.

Living With Repeated Injections

The emotional challenge often becomes easier after the first treatment. Many experienced patients say the anticipation is more uncomfortable than the injection, although responses differ. A good clinical team explains each step, allows time for numbing medicine to work, and adjusts technique when a patient has had significant discomfort.

Long-term treatment can create practical burdens involving transportation, appointment schedules, insurance authorization, copayments, and caregiver time. Patients should discuss these obstacles rather than quietly skipping visits. Clinics may offer financial-support information, appointment coordination, or help selecting an approved product covered by the patient’s plan.

Progress is not judged only by whether the eye chart suddenly becomes easier to read. Stabilizing vision, reducing retinal fluid, preventing bleeding, and lowering the risk of severe future loss are meaningful successes. Some people improve quickly, others improve gradually, and some receive treatment mainly to prevent further decline.

Consistency matters. Anti-VEGF medicine suppresses disease activity for a limited period; it does not permanently remove the biological tendency to leak or grow abnormal vessels. Regular monitoring lets the specialist adjust treatment before a quiet retina becomes an unruly one again.

Questions to Ask the Retina Specialist

• Which condition is Eylea treating in my eye?
• Am I receiving Eylea 2 mg, Eylea HD, or a biosimilar?
• How many loading doses are planned?
• What changes on my OCT scan indicate that treatment is working?
• Which symptoms require an immediate phone call?
• Could glaucoma, a recent cardiovascular event, pregnancy, or another condition change my plan?
• What happens if retinal fluid returns between appointments?
• Are financial-assistance or insurance-support programs available?

Conclusion

Aflibercept is an important anti-VEGF therapy for wet AMD, retinal vein occlusion-related macular edema, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity. By trapping VEGF and related growth signals, Eylea can reduce leakage, control abnormal blood-vessel activity, and help preserve vision.

Standard Eylea dosing varies substantially by diagnosis, and Eylea HD follows separate schedules. The medication must be administered by a qualified eye specialist under sterile conditions. Common effects such as temporary irritation or a surface blood spot are usually manageable, but increasing pain, redness, light sensitivity, flashes, sudden floaters, or declining vision requires urgent assessment.

The most successful treatment plan combines timely injections with regular retinal imaging, control of underlying medical conditions, and honest communication about side effects or appointment barriers. Eye injections may never become anyone’s favorite calendar event, but they can be remarkably valuable appointments when the goal is protecting sight.